exposed-hypodermic-needle-300x200-5715270The makers of the anti-addiction drug Vivitrol – whose controversial nationwide lobbying campaign was spotlighted by the New York Times last week – appear to be getting results in Albany.

A bill advancing in the Assembly would bar insurers from requiring prior authorization for certain drugs used in the treatment of opioid addiction, including “long-acting injectable naltrexone.” Vivitrol, manufactured by Alkermes, is the brand name for the injectable form of naltrexone.

The legislation also applies to methadone and buprenorphine, anti-addiction drugs that are available in generic form. The reference to “long-lasting” and “injectable” would appear to leave out generic versions of naltrexone.

Under prior authorization, health plans will not cover certain medications and procedures unless the treating physician gets their approval in advance. Plans often apply the rule to brand-name drugs as a way of controlling costs when less-expensive alternatives are available. Under the bill, however, health plans could not challenge a doctor’s decision to prescribe Vivitrol, which typically costs about $1,000 for a shot that lasts one month.

The Assembly bill, sponsored by Dan Quart of Manhattan, was advanced by the Insurance Committee on Monday and by the Codes Committee on Tuesday. It is currently awaiting action by the Rules Committee, a last stop before a vote by the full Assembly.

A companion bill in the Senate was introduced by George Amedore of Rotterdam last week. It also awaits action by the Rules Committee.

As reported by the Times, the makers of Vivitrol have gained market share by portraying it as preferable to drugs like buprenorphine and methadone, which are themselves opioids used in controlled doses to manage cravings. Vivitrol, on the other hand, is designed to block opioid receptors in the brain, which prevents users from getting high and, in theory, helps break their addiction.

Some experts told the Times, however, that there is not yet scientific evidence to document that Vivitrol is as effective as competing treatments.

Despite those doubts, 39 states have moved to cover Vivitrol through their Medicaid program, up from 15 five years ago, the Times said. New York lawmakers joined the trend in 2016, as part of a package negotiated by Governor Andrew Cuomo in response to the opioid abuse epidemic.

Over the past year, under pressure from Attorney General Eric Schneiderman, two major insurers – Cigna and Anthem – have agreed to end prior authorization for medication-assisted treatment drugs. Those agreements, signed in October and January, cover the broad range of available medications, including both injectable and oral naltrexone

The current bill – one of 11 opioid-related measures that Cuomo is reportedly supporting this year – would expand the ban on prior authorization for certain medication-assisted treatment drugs to a portion of New York’s commercial health plans, primarily those sold to individuals and small groups. Most large groups are exempt from state regulation under federal law.

If enacted, the legislation would add to the dozens of mandates that the state already imposes on health plans, adding substantially to New York’s high premiums. Many go beyond the recommendations of medical experts, and none is subjected to independent cost-benefit analysis. The Amedore-Quart bill is one of at least 100 proposals currently pending in the Legislature, 26 of which have majority-party sponsors in both houses.

 

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

Hochul’s Emergency Order Imposes Insurer Restrictions Sought by Hospital Group

Buried in Governor Hochul's emergency order on health-care staffing is a temporary bar against insurance companies challenging claims submitted by hospitals–and an influential hospital association is taking credit. Read More

Home Care Agencies Project Widespread Staffing Shortages in the Next Phase of New York’s Vaccine Mandate

Agencies providing home-based care to elderly and disabled New Yorkers face a large-scale loss of employees when the next phase of the state's vaccine mandate takes effect on Oct. 7, according to a newly released industry s Read More

New York’s health benefits remain the second-costliest in the U.S.

New York's health benefit costs increased faster than the national average in 2020, leaving it with the second-least affordable coverage in the U.S. The state's average total cost f Read More

The Health Department’s FOIL Responses Signal an Indefinite Wait for Pandemic Data

The quest for comprehensive data on New York's coronavirus pandemic hit a bureaucratic roadblock this week Read More

A Study of COVID-19 in Nursing Homes Raises Doubt About New York’s Minimum Staffing Law

A newly published study of COVID-19 in nursing homes links larger numbers of employees to higher rates of infection and death for residents – raising fresh doubts about New York's recently enacted "safe staffing" law. Read More

Health Research Inc. Turns Over its Payroll Records Despite Claiming To Be Exempt from FOIL

The full payroll records of more than 2,400 de facto state employees are available to the public for the first time after being released by Health Research Inc. Read More

New York’s Medicaid Rolls Kept Pace with a Nationwide Surge During the Pandemic

New York's Medicaid and Child Health Plus programs added three-quarters of a million enrollees during the coronavirus pandemic, roughly matching the pace of a national surge in sign-ups. Read More

New York’s State Share of Medicaid Spending is Due to Jump 22 Percent This Fiscal Year

The state share of Medicaid spending is projected to jump 22 percent under the recently approved state budget, an unusually steep one-year jump for what is already one of New York's biggest expenditures. Read More

Subscribe

Sign up to receive updates about Empire Center research, news and events in your email.

CONTACT INFORMATION

Empire Center for Public Policy
30 South Pearl St.
Suite 1210
Albany, NY 12207

Phone: 518-434-3100

General Inquiries: Info@EmpireCenter.org

Press Inquiries: Press@EmpireCenter.org

About

The Empire Center is an independent, non-partisan, non-profit think tank located in Albany, New York. Our mission is to make New York a better place to live and work by promoting public policy reforms grounded in free-market principles, personal responsibility, and the ideals of effective and accountable government.

Empire Center Logo Enjoying our work? Sign up for email alerts on our latest news and research.
Together, we can make New York a better place to live and work!